Mapping variants in thyroid hormone transporter MCT8 to disease severity by genomic, phenotypic, functional, structural and deep learning integration.
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Authors
Abstract
Predicting and quantifying phenotypic consequences of genetic variants in rare disorders is a major challenge, particularly pertinent for 'actionable' genes such as thyroid hormone transporter MCT8 (encoded by the X-linked SLC16A2 gene), where loss-of-function (LoF) variants cause a rare neurodevelopmental and (treatable) metabolic disorder in males. The combination of deep phenotyping data with functional and computational tests and with outcomes in population cohorts, enabled us to: (i) identify the genetic aetiology of divergent clinical phenotypes of MCT8 deficiency with genotype-phenotype relationships present across survival and 24 out of 32 disease features; (ii) demonstrate a mild phenocopy in ~400,000 individuals with common genetic variants in MCT8; (iii) assess therapeutic effectiveness, which did not differ among LoF-categories; (iv) advance structural insights in normal and mutated MCT8 by delineating seven critical functional domains; (v) create a pathogenicity-severity MCT8 variant classifier that accurately predicted pathogenicity (AUC:0.91) and severity (AUC:0.86) for 8151 variants. Our information-dense mapping provides a generalizable approach to advance multiple dimensions of rare genetic disorders.
Description
Acknowledgements: Our study was funded by Eurostars (project number E11337; to W.E.V.), the Sherman Foundation (to W.E.V.). The centres in Rotterdam, Bucharest, Paris and Angers are part of the European Reference Network (ERN) on rare endocrine conditions (Endo-ERN). The centres in Rome and Amsterdam are members of the ERN for rare neurological disorders (ERN-RND) and the centres in Naples and Gdansk are members of ERN-ITHACA. The centre in Cambridge (UK) is supported by the Wellcome Trust (Investigator Award 210755/Z/18/Z to K.C.) and the National Institute of Health Research Cambridge Biomedical Research Centre. Funding by NIMH (funding number R01MH118281) to C.H.C). This research has been conducted using the UK Biobank Resource under application numbers 20272, 67864 and 27412. We thank the patients and their families and caregivers who participated in this study.
Journal Title
Conference Name
Journal ISSN
2041-1723

